Ipsen Shares Decline Over 2% and Break Below Short-Term Moving Averages
In mid-morning trading in Paris, the biopharmaceutical company continues its decline in a downward-trending Parisian market. The stock is erasing some of the gains made in recent weeks and appears technically weakened, while the consensus among analysts remains generally neutral on the stock.
The Stock Falls Below Its Short-Term Moving Averages and Nears Its Support at €154.40
Ipsen shares are down 2.18% at €157.10, bringing its weekly decline to 5.36%. The stock has fallen below its MM20 (€163.72, a -4.04% deviation) and MM50 (€160.94, a -2.39% deviation), after hitting resistance at €170.80 at the end of June. The RSI at 46 remains neutral, with no sign of overselling.
However, the stock still maintains a comfortable cushion above its MM200 at €143.92, with a +9.16% deviation, indicating the strength of the medium-term trend and a nearly 50% increase over the year. The next support level to watch on the downside is at €154.40.
A Decline Following Clinical Announcements and Recent External Growth Operations
Today's decline is part of a consolidation phase that began after the Phase III results for Dysport were announced on July 9, for the prevention of migraines. The company had expanded its operations in June and early July, with the acquisitions of Kartos Therapeutics for $450 million in oncology and Memo Therapeutics for up to €700 million in rare diseases. Regarding analyst opinions, CIC Market Solutions reaffirmed its buy rating on July 15, with a target price maintained at €175.00, representing a potential of about 11% from the current price. When the 2026 accounts were published at the end of May, the company highlighted the clinical results of IQIRVO, with an improvement observed in 67% of treated patients.
